

AGENDA

Drug Development Interest Group Meeting

Date: 15. October 2018

Time: 13:00-14:30

Venue: Congress Center Düsseldorf

Room: Level 0, Meeting Room 34

1. Welcome

2. Approval of agenda

3. Who we are: DDC in the EANM - Mission, interaction and involvements

4. Recent activities within the committee:

- Scientific programme/Science

New achievements: Fluorine mapping and radiochemistry for drug molecules - osimertinib case study

Graham Smith, PhD, Team Leader (PET Radiochemistry), Institute of Cancer Research, London, UK, followed by audience feedback and discussion

Drug molecules represent a convenient starting point for radiopharmaceutical probe development. The third generation mutant EGFR inhibitor osimertinib is used as a case study to describe the challenges of design, radiolabelling and biological evaluation with this class of small molecule. Perspectives on lessons learned from this project will be shared.

- Guidelines
- Education/ESMIT
- External collaborations
- Communication

5. Other items

6. Closing remarks